UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 42

Sortiert nach

The Discovery of Fluoxetine Hydrochloride (Prozac)

Nature reviews. Drug discovery, 2005-09, Vol.4 (9), p.764-774

2005

Volltextzugriff (PDF)

Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection

Pharmacological reviews, 2008-09, Vol.60 (3), p.358

2008

Volltextzugriff (PDF)

A review of the abuse potential assessment of atomoxetine: a nonstimulant medication for attention-deficit/hyperactivity disorder

Psychopharmacology, 2013-03, Vol.226 (2), p.189-200

2013

Volltextzugriff (PDF)

A Novel Augmentation Strategy for Treating Resistant Major Depression

The American journal of psychiatry, 2001-01, Vol.158 (1), p.131-134

2001

Volltextzugriff (PDF)

The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions

British journal of pharmacology, 2003-02, Vol.138 (4), p.544-553

2003

Volltextzugriff (PDF)

Therapeutic Opportunities for Muscarinic Receptors in the Central Nervous System

Journal of medicinal chemistry, 2000-11, Vol.43 (23), p.4333-4353

2000

Volltextzugriff (PDF)

Role of specific muscarinic receptor subtypes in cholinergic parasympathomimetic responses, in vivo phosphoinositide hydrolysis, and pilocarpine-induced seizure activity

The European journal of neuroscience, 2003-04, Vol.17 (7), p.1403-1410

2003

Volltextzugriff (PDF)

Potent antagonism of 5-HT3 and 5-HT6 receptors by olanzapine

European journal of pharmacology, 2001-11, Vol.430 (2-3), p.341-349

2001

Volltextzugriff (PDF)

Cholinergic dysfunction in a mouse model of Alzheimer disease is reversed by an anti-A beta antibody

The Journal of clinical investigation, 2006-03, Vol.116 (3), p.825-832

2006

Volltextzugriff (PDF)

Amitifadine, a triple monoamine re-uptake inhibitor, reduces nicotine self-administration in female rats

European journal of pharmacology, 2015-10, Vol.764, p.30-37

2015

Volltextzugriff (PDF)

Decreased binding affinity of olanzapine and clozapine for human muscarinic receptors in intact clonal cells in physiological medium

European journal of pharmacology, 2000-03, Vol.390 (3), p.245-248

2000

Volltextzugriff (PDF)

Muscarinic mechanisms of antipsychotic atypicality

Progress in neuro-psychopharmacology & biological psychiatry, 2003-10, Vol.27 (7), p.1125-1143

2003

Volltextzugriff (PDF)

Dual monoamine modulation for improved treatment of major depressive disorder

Journal of clinical psychopharmacology, 2003-02, Vol.23 (1), p.78-86

2003

Volltextzugriff (PDF)

A current review of olanzapine's safety in the geriatric patient: from pre-clinical pharmacology to clinical data

International journal of geriatric psychiatry, 2001-12, Vol.16 (S1), p.S33-S61

2001

Volltextzugriff (PDF)

Muscarinic receptors as a target for drugs treating schizophrenia

Current drug targets. CNS & neurological disorders, 2002-04, Vol.1 (2), p.163

2002

Volltextzugriff (PDF)

Current perspectives on the development of non-biogenic amine-based antidepressants

Pharmacological research, 2001-05, Vol.43 (5), p.411-422

2001

Volltextzugriff (PDF)

Zonisamide Prevents Olanzapine-Associated Hyperphagia, Weight Gain, and Elevated Blood Glucose in Rats

Neuropsychopharmacology (New York, N.Y.), 2008-11, Vol.33 (12), p.2922-2933

2008

Volltextzugriff (PDF)

New approaches to developing antidepressants by enhancing monoaminergic neurotransmission

Expert opinion on investigational drugs, 2003-04, Vol.12 (4), p.531-543

2003

Volltextzugriff (PDF)

The cannabinoid CB1 receptor antagonist SR141716A increases norepinephrine outflow in the rat anterior hypothalamus

European journal of pharmacology, 2001-08, Vol.426 (3), p.R3-R4

2001

Volltextzugriff (PDF)

M 4 muscarinic receptors regulate the dynamics of cholinergic and dopaminergic neurotransmission: relevance to the pathophysiology and treatment of related central nervous system pathologies

The FASEB journal, 2004-09, Vol.18 (12), p.1410-1412

2004

Volltextzugriff (PDF)

The muscarinic M1 agonist xanomeline increases soluble amyloid precursor protein release from chinese hamster ovary-m1 cells

Life sciences (1973), 1995, Vol.57 (12), p.1183-1190

1995

Volltextzugriff (PDF)

Conformationally Constrained Analogues of the Muscarinic Agonist 3-(4-(Methylthio)-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine. Synthesis, Receptor Affinity, and Antinociceptive Activity

Journal of medicinal chemistry, 1998-01, Vol.41 (1), p.109-116

1998

Volltextzugriff (PDF)

Identification of side chains on 1,2,5-thiadiazole-azacycles optimal for muscarinic M1 receptor activation

Bioorganic & medicinal chemistry letters, 1998-10, Vol.8 (20), p.2897-2902

1998

Volltextzugriff (PDF)

Xanomeline, an M 1/M 4 preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice

Schizophrenia research, 2000-05, Vol.42 (3), p.249-259

2000

Volltextzugriff (PDF)

In vitro and in vivo biochemistry of olanzapine: a novel, atypical antipsychotic drug

The journal of clinical psychiatry, 1997, Vol.58 Suppl 10, p.28

1997

Volltextzugriff (PDF)

1 – 25 von 42

Suche als RSS-Feed

Aktive Filter

ThemaMale

ThemaLife Sciences & Biomedicine

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(42)
Mit Volltextzugriff
(38)

Publikationsform

Artikel
(42)

Sprache

Englisch
(42)
Japanisch
(15)

Erscheinungsjahr

n.n

Thema

Science & Technology
(42)
Pharmacology & Pharmacy
(31)
Animals
(25)
Humans
(16)
Biological And Medical Sciences
(14)
Medical Sciences
(14)
Neuropharmacology
(14)
Pharmacology. Drug Treatments
(14)
Rats
(10)
Medicine, Research & Experimental
(8)
Neurosciences & Neurology
(8)
Psychiatry
(8)
Psychopharmacology
(8)
Research & Experimental Medicine
(8)
Chemistry, Medicinal
(7)
Neurosciences
(7)
Psychology. Psychoanalysis. Psychiatry
(7)
Cricetinae
(6)
Dose-Response Relationship, Drug
(6)

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The Discovery of Fluoxetine Hydrochloride (Prozac)

Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection

A review of the abuse potential assessment of atomoxetine: a nonstimulant medication for attention-deficit/hyperactivity disorder

A Novel Augmentation Strategy for Treating Resistant Major Depression

The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions

Therapeutic Opportunities for Muscarinic Receptors in the Central Nervous System

Role of specific muscarinic receptor subtypes in cholinergic parasympathomimetic responses, in vivo phosphoinositide hydrolysis, and pilocarpine-induced seizure activity

Potent antagonism of 5-HT3 and 5-HT6 receptors by olanzapine

Cholinergic dysfunction in a mouse model of Alzheimer disease is reversed by an anti-A beta antibody

Amitifadine, a triple monoamine re-uptake inhibitor, reduces nicotine self-administration in female rats

Decreased binding affinity of olanzapine and clozapine for human muscarinic receptors in intact clonal cells in physiological medium

Muscarinic mechanisms of antipsychotic atypicality

Dual monoamine modulation for improved treatment of major depressive disorder

A current review of olanzapine's safety in the geriatric patient: from pre-clinical pharmacology to clinical data

Muscarinic receptors as a target for drugs treating schizophrenia

Current perspectives on the development of non-biogenic amine-based antidepressants

Zonisamide Prevents Olanzapine-Associated Hyperphagia, Weight Gain, and Elevated Blood Glucose in Rats

New approaches to developing antidepressants by enhancing monoaminergic neurotransmission

The cannabinoid CB1 receptor antagonist SR141716A increases norepinephrine outflow in the rat anterior hypothalamus

M 4 muscarinic receptors regulate the dynamics of cholinergic and dopaminergic neurotransmission: relevance to the pathophysiology and treatment of related central nervous system pathologies

The muscarinic M1 agonist xanomeline increases soluble amyloid precursor protein release from chinese hamster ovary-m1 cells

Conformationally Constrained Analogues of the Muscarinic Agonist 3-(4-(Methylthio)-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine. Synthesis, Receptor Affinity, and Antinociceptive Activity

Identification of side chains on 1,2,5-thiadiazole-azacycles optimal for muscarinic M1 receptor activation

Xanomeline, an M 1/M 4 preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice

In vitro and in vivo biochemistry of olanzapine: a novel, atypical antipsychotic drug

Aktive Filter

Suchergebnisse filtern